Key Takeaways AlloSpan Canal introduces a bio-reinforced approach to glaucoma surgery, combining canaloplasty with a biologic implant to restore natural outflow without synthetic hardware The technology is designed to eliminate the traditional tradeoff between temporary canal expansion and permanent implants in MIGS procedures A controlled US early access program is underway, with broader commercialization anticipated in 2027 Iantrek announced the introduction and US controlled release plan for AlloSpan Canal, a bio-reinforced canal restoration platform for glaucoma. AlloSpan Canal introduces a next-generation approach to trabecular intervention, aiming to resolve a longstanding limitation in glaucoma surgery: the tradeoff between temporary canal expansion and permanent synthetic implants, according to Iantrek. Unlike traditional approaches, AlloSpan Canal combines nitinol-guided canaloplasty with durable biological reinforcement, enabling restoration of Schlemm’s canal without leaving synthetic hardware in the eye. “The goal is to rehabilitate trabecular outflow, which is significantly diminished in patients with glaucoma, through a TM-sparing, minimally invasive approach that restores and maintains Schlemm’s canal,” said Sean Ianchulev, MD, MPH, Professor of Ophthalmology at New York Eye and Ear and Founder of Iantrek. “Bio-reinforced canaloplasty, as enabled by AlloSpan Canal, combines nitinol-based canal intervention with allogeneic biological scaffolding to achieve durable restoration of the canal in a way that is both structurally supportive and biologically integrated.” Dr. Ianchulev is set to formally unveil the technology during the 2026 Kelman Innovation Lecture at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting. Historically, glaucoma surgeons have had to choose between procedures that provide temporary canal expansion (such as viscoelastic canaloplasty) and those that rely on permanent implants to maintain patency. AlloSpan Canal is designed to eliminate this compromise. The platform integrates a trabecular meshwork–sparing, nitinol-guided canaloplasty with placement of a naturally expanding scleral bio-implant composed of homologous tissue. This biologic implant reinforces canal architecture and sustains outflow—without introducing synthetic material into the eye. AlloSpan Canal is classified as an FDA-registered, minimally manipulated homologous use HCT/P and is aligned with an established Category I procedural code, facilitating clinical adoption. “For years, canal-based surgery has been constrained by a forced tradeoff between temporary and permanent procedural offerings,” said Adam Szaronos, CEO of Iantrek. “We believe that constraint is going away. Canal intervention is now positioned to evolve from a procedural trade-off into a durable, restorative treatment strategy.” Early Access Program Underway Following successful first-in-human cases conducted outside the United States, Iantrek is launching a controlled early access program across select U.S. clinical sites. The program will generate real-world data to inform surgical techniques, refine procedural protocols, and evaluate performance ahead of broader commercialization expected in 2027. Surgeons who have observed or participated in early use cases highlight the novelty of the approach. “We’ve had ways to dilate the canal and ways to scaffold it with hardware,” said Arkadiy Yadgarov, MD “This is the first time I’ve seen an approach that dilates the canal and reinforces it biologically. Retaining canal restoration without synthetic hardware is a compelling concept and opens a new chapter for all surgeons performing angle surgery.” The introduction of AlloSpan Canal follows Iantrek's launch of AlloFlo Uveo in October 2025.